News | April 30, 2026
Teva strikes $900M bet on breakthrough Tourette drug with Emalex buyout
The agreement could rise to $900 million if key commercial milestones are met
The agreement could rise to $900 million if key commercial milestones are met
Company confirms seized products were not from its authorised supply chain and urges patients to purchase medicines only through licensed pharmacies
The deals, tied to cases in the US District Court for the District of Delaware, effectively extend US patent protection for VYNDAMAX until June 1, 2031
The aim is to simplify and strengthen long-term control of airway disease through triple therapy in one device
On the generics and biosimilars front, the combined business is expected to benefit from Sun’s portfolio of more than 550 approved ANDAs across multiple dosage forms
Rs. 40 cr buyback, 200% dividend announced
In his new role, Gregory will drive partnerships for the company’s large-scale molecule biologics business across Europe
The product is manufactured at AKUMS’ state-of-the-art injectable facility in Kotdwar, Uttarakhand
The approval was driven by data from the Phase III TULIP-SC trial
The approved ANDA is therapeutically equivalent to the reference listed drug product (RLD), Gilenya Capsules, 0.5 mg of Novartis Pharmaceuticals Corporation (Novartis)
Subscribe To Our Newsletter & Stay Updated
